Skip to main content

Irene De la Calle Fuentes

Institutions of which they are part

Predoctoral researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Irene De la Calle Fuentes

Institutions of which they are part

Predoctoral researcher
Biomedical Research in Gynaecology
Vall Hebron Institut de Recerca

Projects

Development of a non-invasive ivd for endometrial cancer screening on high-risk populations

IP: Eva Colas Ortega
Collaborators: Antonio Gil Moreno, Irene De la Calle Fuentes
Funding agency: Ministerio de Ciencia e Innovación-MICINN
Funding: 201869.5
Reference: CPP2022-009817
Duration: 01/10/2023 - 30/09/2026

Ministerio de Ciencia

Development of a non-invasive ivd for endometrial cancer screening on high-risk populations

IP: Eva Colas Ortega
Collaborators: Antonio Gil Moreno, Irene De la Calle Fuentes
Funding agency: Ministerio Ciencia, Innovación y Universidades
Funding: 201869.5
Reference: CPP2022-009817
Duration: 01/10/2023 - 31/12/2026

Ministerio de Ciencia

Development of a personalised non-invasive diagnosis of endometrial cancer using proteomic markers in cervical fluids and clinical data

IP: Antonio Gil Moreno
Collaborators: Irene De la Calle Fuentes, Miriam Izquierdo Sans
Funding agency: Instituto de Salud Carlos III
Funding: 89900
Reference: IFI22/00019
Duration: 01/01/2023 - 31/12/2026

NUEVAS APROXIMACIONES PARA EL DIAGNÓSTICO DE CÁNCER DE ENDOMETRIO.

IP: Antonio Gil Moreno
Collaborators: Silvia Cabrera Diaz, Marta Rebull Santamaria, Irene De la Calle Fuentes
Funding agency: Ministerio Ciencia, Innovación y Universidades
Funding: 369335
Reference: CPP2021-008440
Duration: 14/02/2022 - 30/09/2025

Ministerio de Ciencia

Related news

The Biomedical Research in Gynaecology group at VHIR has contributed to this international resource with endometrial cancer organoid models.

The ten groups within the Cancer Area combine basic, translational and clinical research to identify new targets, biomarkers and therapeutic strategies

The study evaluated the results of combining SYD985, a HER2 antibody conjugated to a potent cytotoxic drug, and niraparib, an inhibitor of DNA damage repair.

Related professionals

Ainhoa Perez Travesedo

Ainhoa Perez Travesedo

Fundraising Unit
Communication Directorate
Read more
Guillem Navarro Bonet

Guillem Navarro Bonet

Commercial and Academic Clinical Research
Read more
Maria del Carmen Llorente Olmedo

Maria del Carmen Llorente Olmedo

Research assistant
Shock, Organ Dysfunction and Resuscitation
Read more
María López Berral

María López Berral

Research technician
Epidemiology and Public Health
Read more

Subscribe to our newsletters and be part of the Campus life

We are a world-leading healthcare complex where healthcare, research, teaching and innovation go hand in hand.

CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.